METUBINE IODIDE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jan 1949
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Metubine Iodide is a small-molecule injectable drug approved in 1949 by Eli Lilly and Company. The specific indication and mechanism of action are not documented in available data; however, as a legacy NDA product, it likely serves a niche therapeutic need. Historical injectable small molecules of this era were primarily used in anesthesia, neuromuscular blockade, or diagnostic imaging.
LOE Approaching
Product is nearing loss of exclusivity with minimal commercial visibility; team size and investment are likely minimal.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and approaching loss of exclusivity, career opportunities on the Metubine Iodide team are extremely limited. Assignment to this product would involve legacy portfolio maintenance rather than growth or innovation-focused work.
Medical Science LiaisonRegulatory Affairs
Worked on METUBINE IODIDE at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.